VIVUS to present Qnexa phase 3 data at conference

MOUNTAIN VIEW, Calif. A drug company that develops treatments for obesity, diabetes and sexual health will present data on an investigational drug undergoing late-stage clinical development at a diabetes conference in Europe.

VIVUS said Thursday that it would feature the drug Qnexa at the European Association for the Study of Diabetes’ annual meeting in Vienna, Austria, on Friday. The company announced data from two phase 3 trials of the drug last month, showing that it promoted weight loss and improvements in blood sugar, blood pressure and lipid levels. The drug is also in phase 2 development as a treatment for Type 2 diabetes.

“The enthusiasm among physicians, patients and pharmaceutical companies for a new option capable of helping patients achieve such clinically meaningful results is significant,” VIVUS president and CEO Leland Wilson said in a statement.